ATE399156T1 - Neue indol- oder benzimidazol-derivate - Google Patents
Neue indol- oder benzimidazol-derivateInfo
- Publication number
- ATE399156T1 ATE399156T1 AT05806665T AT05806665T ATE399156T1 AT E399156 T1 ATE399156 T1 AT E399156T1 AT 05806665 T AT05806665 T AT 05806665T AT 05806665 T AT05806665 T AT 05806665T AT E399156 T1 ATE399156 T1 AT E399156T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- benzimidazole derivatives
- new indole
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04105329 | 2004-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE399156T1 true ATE399156T1 (de) | 2008-07-15 |
Family
ID=35658930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05806665T ATE399156T1 (de) | 2004-10-27 | 2005-10-18 | Neue indol- oder benzimidazol-derivate |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7384945B2 (de) |
| EP (1) | EP1807398B1 (de) |
| JP (1) | JP2008517959A (de) |
| KR (1) | KR100912146B1 (de) |
| CN (1) | CN101048382B (de) |
| AT (1) | ATE399156T1 (de) |
| AU (1) | AU2005298986A1 (de) |
| BR (1) | BRPI0517369A (de) |
| CA (1) | CA2585030A1 (de) |
| DE (1) | DE602005007765D1 (de) |
| ES (1) | ES2309812T3 (de) |
| MX (1) | MX2007004910A (de) |
| RU (1) | RU2394027C2 (de) |
| WO (1) | WO2006045478A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1891952B1 (de) * | 2006-05-04 | 2011-10-05 | LEK Pharmaceuticals d.d. | Pharmazeutische Zusammensetzung mit Olmesartan-Medoxomil |
| US8957093B2 (en) | 2011-06-06 | 2015-02-17 | The Scripps Research Institute | N-biphenylmethylindole modulators of PPARG |
| US9051265B2 (en) | 2011-06-06 | 2015-06-09 | The Scripps Research Institute | N-benzylindole modulators of PPARG |
| WO2013078240A1 (en) | 2011-11-22 | 2013-05-30 | Ripka Amy S | N-biphenylmethylbenzimidazole modulators of pparg |
| AU2012345779B2 (en) | 2011-12-01 | 2017-04-06 | Chemocentryx, Inc. | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists |
| EP2785692B1 (de) * | 2011-12-01 | 2017-09-27 | ChemoCentryx, Inc. | Substituierte aniline als ccr(4)-antagonisten |
| EP2794561B1 (de) * | 2011-12-21 | 2018-08-22 | Allergan, Inc. | Verbindungen zur wirkung auf mehrere prostaglandinrezeptoren mit einer allgemeinen entzündungshemmenden reaktion |
| US9550737B2 (en) | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
| WO2015161108A1 (en) | 2014-04-16 | 2015-10-22 | The Scripps Research Institute | Pparg modulators for treatment of osteoporosis |
| WO2017035114A1 (en) * | 2015-08-25 | 2017-03-02 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as cb-1 inverse agonists |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940418A (en) | 1972-04-07 | 1976-02-24 | G. D. Searle & Co. | Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
| US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| CZ293016B6 (cs) * | 1995-06-01 | 2004-01-14 | Sankyo Company Limited | Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem |
| JPH10508321A (ja) * | 1995-09-01 | 1998-08-18 | イーライ・リリー・アンド・カンパニー | インドリル神経ペプチドyレセプターアンタゴニスト |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| HUP9900625A3 (en) * | 1995-12-28 | 2003-04-28 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives, pharmaceutical compositions containing them and process for preparing the compounds |
| KR20010041346A (ko) * | 1998-02-25 | 2001-05-15 | 브루스 엠. 에이센, 토마스 제이 데스로저 | 포스포리파제 a2 억제제 |
| EA200000868A1 (ru) * | 1998-02-25 | 2001-04-23 | Дженетикс Инститьют, Инк. | Ингибиторы фосфолипаз |
| IL141769A0 (en) | 1998-09-11 | 2002-03-10 | Aventis Pharma Sa | Azetidine derivatives, preparation and medicines containing them |
| FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| GB9919411D0 (en) * | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| FR2800375B1 (fr) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| US6479479B2 (en) | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| US6355631B1 (en) | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| FR2805810B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| UA74367C2 (uk) | 2000-03-23 | 2005-12-15 | Сольве Фармас'Ютікалз Б.В. | ПОХІДНІ 4,5-ДИГІДРО-1Н-ПІРАЗОЛУ, ЩО ВИЯВЛЯЮТЬ АНТАГОНІСТИЧНУ АКТИВНІСТЬ ЩОДО СВ<sub>1</sub>, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЇЇ ВИГОТОВЛЕННЯ, СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ (ВАРІАНТИ) |
| FR2814678B1 (fr) | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| SE0101387D0 (sv) | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | Novel compounds |
| WO2003005393A1 (de) * | 2001-06-29 | 2003-01-16 | Siemens Aktiengesellschaft | Vakuumschaltröhre für hohe kurzschlussströme |
| AU2002347022A1 (en) | 2001-12-20 | 2003-07-09 | Novo Nordisk A/S | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
| EP1618090A1 (de) * | 2003-04-11 | 2006-01-25 | Novo Nordisk A/S | 11 beta-hydroxysteroiddehydrogenase-typ-1-aktive verbindungen |
| SE0301701D0 (sv) * | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
-
2005
- 2005-10-18 CA CA002585030A patent/CA2585030A1/en not_active Abandoned
- 2005-10-18 AU AU2005298986A patent/AU2005298986A1/en not_active Abandoned
- 2005-10-18 BR BRPI0517369-8A patent/BRPI0517369A/pt not_active IP Right Cessation
- 2005-10-18 WO PCT/EP2005/011176 patent/WO2006045478A1/en not_active Ceased
- 2005-10-18 EP EP05806665A patent/EP1807398B1/de not_active Expired - Lifetime
- 2005-10-18 AT AT05806665T patent/ATE399156T1/de active
- 2005-10-18 CN CN2005800366958A patent/CN101048382B/zh not_active Expired - Fee Related
- 2005-10-18 JP JP2007538299A patent/JP2008517959A/ja not_active Ceased
- 2005-10-18 DE DE602005007765T patent/DE602005007765D1/de not_active Expired - Lifetime
- 2005-10-18 ES ES05806665T patent/ES2309812T3/es not_active Expired - Lifetime
- 2005-10-18 RU RU2007119638/04A patent/RU2394027C2/ru not_active IP Right Cessation
- 2005-10-18 MX MX2007004910A patent/MX2007004910A/es active IP Right Grant
- 2005-10-18 KR KR1020077011823A patent/KR100912146B1/ko not_active Expired - Fee Related
- 2005-10-25 US US11/257,885 patent/US7384945B2/en not_active Expired - Fee Related
-
2008
- 2008-05-02 US US12/114,219 patent/US7786128B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007119638A (ru) | 2008-12-10 |
| BRPI0517369A (pt) | 2008-10-07 |
| KR20070084545A (ko) | 2007-08-24 |
| MX2007004910A (es) | 2007-06-14 |
| RU2394027C2 (ru) | 2010-07-10 |
| US20080234290A1 (en) | 2008-09-25 |
| CA2585030A1 (en) | 2006-05-04 |
| KR100912146B1 (ko) | 2009-08-14 |
| WO2006045478A1 (en) | 2006-05-04 |
| AU2005298986A1 (en) | 2006-05-04 |
| US7384945B2 (en) | 2008-06-10 |
| US20060089367A1 (en) | 2006-04-27 |
| DE602005007765D1 (de) | 2008-08-07 |
| EP1807398A1 (de) | 2007-07-18 |
| US7786128B2 (en) | 2010-08-31 |
| ES2309812T3 (es) | 2008-12-16 |
| EP1807398B1 (de) | 2008-06-25 |
| JP2008517959A (ja) | 2008-05-29 |
| CN101048382A (zh) | 2007-10-03 |
| CN101048382B (zh) | 2010-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
| ATE517882T1 (de) | Chinolinderivate | |
| ATE496620T1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| EP2178869A4 (de) | Indolverbindungen als hemmer von zellnekrose | |
| MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. | |
| WO2008048981A3 (en) | Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
| NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
| ATE384058T1 (de) | Thiazolderivate | |
| TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
| NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
| ATE430744T1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
| TW200612936A (en) | Indole derivatives | |
| TW200738651A (en) | Cyclohexyl sulfonamide derivatives | |
| ATE492534T1 (de) | 1h-indol-5-ylpiperazin-1-ylmethanonderivate | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
| TW200626158A (en) | Naphthaline derivatives | |
| ATE466842T1 (de) | 3-substituierte pyridinderivate als h3- antagonisten | |
| ATE495159T1 (de) | Diaminocyclohexan- und diaminocyclopentanderivate | |
| ATE399156T1 (de) | Neue indol- oder benzimidazol-derivate | |
| DE602006014305D1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
| ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| MY157425A (en) | Substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | |
| DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
| TW200637817A (en) | 5-aminoindole derivatives | |
| ATE481395T1 (de) | Cyclohexylderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1807398 Country of ref document: EP |